Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Trecondyv treosulfan Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric) CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Trecondyv treosulfan Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) Reimburse with clinical criteria and/or conditions Active
Trelegy Ellipta fluticasone furoate/umeclidinium bromide/vilanterol trifenatate Asthma, maintenance CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Trelegy Ellipta fluticasone furoate umeclidinium vilanterol Chronic obstructive pulmonary disease (COPD) Reimburse with clinical criteria and/or conditions Complete
Trelstar Triptorelin pamoate Cancer, prostate List in a similar manner to other drugs in class Complete
Tremfya guselkumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Tremfya guselkumab Psoriatic arthritis Reimburse with clinical criteria and/or conditions Complete
Tresiba insulin degludec Diabetes mellitus, Type 1 & 2 Reimburse with clinical criteria and/or conditions Complete
Tridural Tramadol hydrochloride Pain Do not list Complete
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older Active